Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $31.1 million.

  • Taysha Gene Therapies' Non-cash Items rose 9217.9% to $31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year increase of 9217.9%. This contributed to the annual value of $15.5 million for FY2024, which is 69081.63% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Non-cash Items of $31.1 million as of Q3 2025, which was up 9217.9% from $22.2 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Non-cash Items peaked at $47.4 million during Q1 2022, and registered a low of $62000.0 during Q4 2022.
  • Its 4-year average for Non-cash Items is $19.3 million, with a median of $16.9 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Taysha Gene Therapies' Non-cash Items was 306129.03% (2023), while the steepest drop was 7341.77% (2023).
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Non-cash Items stood at $62000.0 in 2022, then surged by 3061.29% to $2.0 million in 2023, then skyrocketed by 690.82% to $15.5 million in 2024, then surged by 100.86% to $31.1 million in 2025.
  • Its Non-cash Items was $31.1 million in Q3 2025, compared to $22.2 million in Q2 2025 and $22.2 million in Q1 2025.